Biomx Inc
PHGE3.930USD
-0.580-12.72%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
5.54MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Biomx Inc Unternehmen
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Biomx Inc Informationen
BörsenkürzelPHGE
Name des UnternehmensBiomx Inc
IPO-datumDec 18, 2018
CEOSolomon (Jonathan Eitan)
Anzahl der mitarbeiter52
WertpapierartOrdinary Share
GeschäftsjahresendeDec 18
Addresse22 Einstein St.
StadtNESS-ZIONA
BörseNASDAQ OMX – NASDAQ Basic Amex
LandIsrael
Postleitzahl7414003
Telefon972723942377
Websitehttps://www.biomx.com/
BörsenkürzelPHGE
IPO-datumDec 18, 2018
CEOSolomon (Jonathan Eitan)
Führungskräfte von Biomx Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-1.00%
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Mr. Gregory Merril
Mr. Gregory Merril
Independent Director
Independent Director
--
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
9.46K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
5.86K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
3.63K
-1.00%
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Feb 1
Aktualisiert: Sun, Feb 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
Andere
65.03%
Aktionäre
Aktionäre
Anteil
Deerfield Management Company, L.P.
8.60%
Cystic Fibrosis Foundation
8.60%
Nantahala Capital Management, LLC
8.60%
Alyeska Investment Group, L.P.
5.48%
Centaurus Investments Limited
3.69%
Andere
65.03%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
26.70%
Corporation
12.29%
Holding Company
3.69%
Venture Capital
3.36%
Private Equity
2.50%
Research Firm
1.49%
Individual Investor
1.33%
Investment Advisor/Hedge Fund
0.36%
Investment Advisor
0.23%
Andere
48.05%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
41
528.98K
34.65%
-249.43K
2025Q3
38
10.55M
39.72%
-5.15M
2025Q2
48
19.36M
73.97%
+6.20M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Deerfield Management Company, L.P.
131.27K
8.6%
--
--
Sep 30, 2025
Cystic Fibrosis Foundation
131.27K
8.6%
+37.18K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
131.23K
8.6%
--
--
Sep 30, 2025
Alyeska Investment Group, L.P.
83.72K
5.48%
+83.72K
--
Sep 30, 2025
Centaurus Investments Limited
56.32K
3.69%
+56.32K
--
Apr 21, 2025
AMR Action Fund LP
46.15K
3.02%
+30.07K
+187.05%
Sep 30, 2024
Telmina Ltd
29.49K
1.93%
+14.54K
+97.30%
Sep 30, 2024
Nimble Ventures LLC
26.85K
1.76%
--
--
Sep 30, 2024
J.P. Morgan Securities LLC
22.63K
1.48%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
